Japan Dose Regimen Study of AZD1656 in Japanese Type 2 Diabetes Mellitus Patients

Model scores of the 29,894 trials active now.

Model score 9% for any early termination, 1% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2011-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: diseasepatientspriorpurpose ofthe purpose
  Phrases that lowered it: efficacyjapanesemedical historyevaluatethe effect
• Accepts healthy volunteers: No (raises risk) · Who can join
• Minimum age: 20 (lowers risk) · Who can join
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 373 (raises risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor's past trials: 811 (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Sponsor's past termination rate: 7.4% (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Blinding: double (raises risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Maximum age: not given (lowers risk) · Who can join
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Disease area, neurology: No (lowers risk) · Disease area
• Disease area, metabolic: Yes (lowers risk) · Disease area
• Responsible party: sponsor (lowers risk) · Design
• Keywords listed: 7 (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients NCT00916604 · started 2009 · scored riskier than 37% of active trials completed
• Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes NCT00856908 · started 2009 · scored riskier than 20% of active trials completed
• A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes NCT00747175 · started 2008 · scored riskier than 10% of active trials completed
• To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Insulin NCT00768105 · started 2008 · scored riskier than 8% of active trials completed
• Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 in Patients With Type 2 Diabetes Mellitus Treated With Metformin NCT00817778 · started 2009 · scored riskier than 18% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.